Exhibit 99.1
 
 COMPANY CONTACT:
    
    INVESTOR CONTACTS:Endologix, Inc.
    
    Lippert/Heilshorn & Associates, Inc.John McDermott, CEO
    
    Bruce Voss (bvoss@lhai.com)(949) 595-7200
    
    Jody Cain (jcain@lhai.com)www.endologix.com
    
    (310) 691-7100
 ENDOLOGIX REPORTS 36% REVENUE GROWTH IN 2008
 Record Fourth Quarter and 16 th Consecutive Quarter of Domestic Sales Growth
 Conference Call Begins at 5:00 p.m. Eastern Time Today
 IRVINE, Calif. (February 19, 2009)  Endologix, Inc. (Nasdaq: ELGX), ®
 ®
  Financial Results
  
     www.endologix.com




---



##### 



Conference Call Information
  
     www.endologix.com




---



##### 



www.endologix.com
 About Endologix
 www.endologix.com
 Except for historical information contained herein, this news release contains forward-looking
statements, specifically with respect to new product introductions and 2009 financial guidance for
revenue, gross margins, and cash flow, the accuracy of which are necessarily subject to risks and
uncertainties, all of which are difficult or impossible to predict accurately and many of which are
beyond the control of Endologix. Many factors may cause actual results to differ materially from
anticipated results, including the success of sales efforts for the Powerlink System and related
new products, product research and development efforts, and other economic, business, competitive
and regulatory factors. The Company undertakes no obligation to update its forward looking
statements. Please refer to the Companys Annual Report on Form 10-K for the year ended December
31, 2007, and the Companys other filings with the Securities and Exchange Commission, for more
detailed information regarding these risks and other factors that may cause actual results to
differ materially from those expressed or implied.
  
     www.endologix.com




---



##### 



ENDOLOGIX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)
 (In thousands, except per share amounts)
 Three Months Ended
    
    
    Twelve Months EndedDecember 31,
    
    
    December 31,2008
    
    
    2007
    
    
    2008
    
    
    2007Revenue:Domestic Product Revenue
    
    $
    9,128
    
    
    $
    6,742
    
    
    $
    31,936
    
    
    $
    23,049Non-US Product Revenue
    
    
    1,551
    
    
    
    1,175
    
    
    
    5,695
    
    
    
    3,968Total Product Revenue
    
    
    10,679
    
    
    
    7,917
    
    
    
    37,631
    
    
    
    27,017License Revenue
    
    
    
    
    
    
    76
    
    
    
    33
    
    
    
    754Total revenue
    
    
    10,679
    
    
    
    7,993
    
    
    
    37,664
    
    
    
    27,771Cost of product revenue
    
    
    2,835
    
    
    
    2,890
    
    
    
    10,380
    
    
    
    10,539Gross profit
    
    
    7,844
    
    
    
    5,103
    
    
    
    27,284
    
    
    
    17,232Operating expenses:Research, development and clinical
    
    
    1,352
    
    
    
    1,707
    
    
    
    6,060
    
    
    
    6,372Marketing and sales
    
    
    5,777
    
    
    
    5,476
    
    
    
    23,794
    
    
    
    20,142General and administrative
    
    
    2,207
    
    
    
    1,678
    
    
    
    9,477
    
    
    
    6,380Termination of supply agreement
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    550Total operating expenses
    
    
    9,336
    
    
    
    8,861
    
    
    
    39,331
    
    
    
    33,444Loss from operations
    
    
    (1,492
    )
    
    
    (3,758
    )
    
    
    (12,047
    )
    
    
    (16,212
    )Other income (loss):Interest income (expense)
    
    
    (37
    )
    
    
    106
    
    
    
    22
    
    
    
    664Other income (expense)
    
    
    (47
    )
    
    
    124
    
    
    
    33
    
    
    
    473Total other income (expense)
    
    
    (84
    )
    
    
    230
    
    
    
    55
    
    
    
    1,137Net loss
    
    
    ($1,576
    )
    
    
    ($3,528
    )
    
    
    ($11,992
    )
    
    
    ($15,075
    )Basic and diluted net loss per share
    
    
    ($0.04
    )
    
    
    ($0.08
    )
    
    
    ($0.28
    )
    
    
    ($0.35
    )Shares used in computing basic and
diluted net loss per share
    
    
    43,127
    
    
    
    42,881
    
    
    
    43,045
    
    
    
    42,796
     www.endologix.com




---



##### 



ENDOLOGIX, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
  December 31,
    
    
    December 31,2008
    
    
    2007ASSETSCurrent assets:Cash and cash equivalents
    
    $
    7,611
    
    
    $
    8,728Restricted cash equivalents
    
    
    500
    
    
    
    500Marketable securities available-for-sale
    
    
    
    
    
    
    Accounts receivable, net
    
    
    6,371
    
    
    
    4,527Other receivables
    
    
    3
    
    
    
    234Inventories
    
    
    7,099
    
    
    
    8,054Other current assets
    
    
    443
    
    
    
    581Total current assets
    
    
    22,027
    
    
    
    22,624Property and equipment, net
    
    
    2,993
    
    
    
    3,771Marketable securities available-for-sale
    
    
    
    
    
    
    Goodwill
    
    
    4,631
    
    
    
    4,631Intangibles, net
    
    
    7,508
    
    
    
    8,913Other assets
    
    
    104
    
    
    
    104Total Assets
    
    $
    37,263
    
    
    $
    40,043LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payable and accrued expenses
    
    $
    5,401
    
    
    $
    4,259Current portion of long term debt
    
    
    750
    
    
    
    Current liabilities
    
    
    6,151
    
    
    
    4,259Long term liabilities:Long term debt
    
    $
    4,250
    
    
    $
    Other long term liabilities
    
    
    1,045
    
    
    
    1,109Long term liabilities
    
    
    5,295
    
    
    
    1,109Total liabilities
    
    
    11,446
    
    
    
    5,368Stockholders equity:Convertible preferred stock, $.001 par value;
5,000 shares authorized, no shares issued and
outstandingCommon stock, $.001 par value; 60,000 shares
authorized, 44,365 and 43,453 shares issued, and
43,870 and 42,958 outstanding
    
    
    44
    
    
    
    43Additional paid-in capital
    
    
    170,239
    
    
    
    166,912Accumulated deficit
    
    
    (143,730
    )
    
    
    (131,738
    )Treasury stock, at cost, 495 shares
    
    
    (661
    )
    
    
    (661
    )Accumulated other comprehensive income
    
    
    (75
    )
    
    
    119Total stockholders equity
    
    
    25,817
    
    
    
    34,675Total Liabilities and Stockholders Equity
    
    $
    37,263
    
    
    $
    40,043
     www.endologix.com